Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$14.1 million.

  • Phathom Pharmaceuticals' Cash from Operations rose 7779.72% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.2 million, marking a year-over-year increase of 885.47%. This contributed to the annual value of -$266.8 million for FY2024, which is 9390.17% down from last year.
  • Phathom Pharmaceuticals' Cash from Operations amounted to -$14.1 million in Q3 2025, which was up 7779.72% from -$62.7 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Cash from Operations registered a high of -$14.1 million during Q3 2025, and its lowest value of -$84.9 million during Q1 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' median Cash from Operations value was -$43.8 million (recorded in 2023), while the average stood at -$47.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 21856.31% in 2024, then skyrocketed by 7779.72% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Cash from Operations stood at -$41.0 million in 2022, then dropped by 6.72% to -$43.8 million in 2023, then crashed by 44.89% to -$63.5 million in 2024, then soared by 77.76% to -$14.1 million in 2025.
  • Its last three reported values are -$14.1 million in Q3 2025, -$62.7 million for Q2 2025, and -$84.9 million during Q1 2025.